» Articles » PMID: 34789774

Deep Learning for the Prediction of Early On-treatment Response in Metastatic Colorectal Cancer from Serial Medical Imaging

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Nov 18
PMID 34789774
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

In current clinical practice, tumor response assessment is usually based on tumor size change on serial computerized tomography (CT) scan images. However, evaluation of tumor response to anti-vascular endothelial growth factor therapies in metastatic colorectal cancer (mCRC) is limited because morphological change in tumor may occur earlier than tumor size change. Here we present an analysis utilizing a deep learning (DL) network to characterize tumor morphological change for response assessment in mCRC patients. We retrospectively analyzed 1,028 mCRC patients who were prospectively included in the VELOUR trial (NCT00561470). We found that DL network was able to predict early on-treatment response in mCRC and showed better performance than its size-based counterpart with C-Index: 0.649 (95% CI: 0.619,0.679) vs. 0.627 (95% CI: 0.567,0.638), p = 0.009, z-test. The integration of DL network with size-based methodology could further improve the prediction performance to C-Index: 0.694 (95% CI: 0.661,0.720), which was superior to size/DL-based-only models (all p < 0.001, z-test). Our study suggests that DL network could provide a noninvasive mean for quantitative and comprehensive characterization of tumor morphological change, which may potentially benefit personalized early on-treatment decision making.

Citing Articles

A pelvis MR transformer-based deep learning model for predicting lung metastases risk in patients with rectal cancer.

Li Y, Li S, Xiao R, Li X, Yi Y, Zhang L Front Oncol. 2025; 15:1496820.

PMID: 39980546 PMC: 11841465. DOI: 10.3389/fonc.2025.1496820.


Improving the prediction of patient survival with the aid of residual convolutional neural network (ResNet) in colorectal cancer with unresectable liver metastases treated with bevacizumab-based chemotherapy.

Chiu S, Li H, Chang W, Wu C, Lin H, Lo C Cancer Imaging. 2024; 24(1):165.

PMID: 39696483 PMC: 11654025. DOI: 10.1186/s40644-024-00809-1.


Advancements and Challenges in the Image-Based Diagnosis of Lung and Colon Cancer: A Comprehensive Review.

Patharia P, Sethy P, Nanthaamornphong A Cancer Inform. 2024; 23:11769351241290608.

PMID: 39483315 PMC: 11526153. DOI: 10.1177/11769351241290608.


Integrating machine learning and artificial intelligence in life-course epidemiology: pathways to innovative public health solutions.

Chen S, Yu J, Chamouni S, Wang Y, Li Y BMC Med. 2024; 22(1):354.

PMID: 39218895 PMC: 11367811. DOI: 10.1186/s12916-024-03566-x.


Multiregional dynamic contrast-enhanced MRI-based integrated system for predicting pathological complete response of axillary lymph node to neoadjuvant chemotherapy in breast cancer: multicentre study.

Li Z, Gao J, Zhou H, Li X, Zheng T, Lin F EBioMedicine. 2024; 107:105311.

PMID: 39191174 PMC: 11400626. DOI: 10.1016/j.ebiom.2024.105311.


References
1.
Kang L, Chen W, Petrick N, Gallas B . Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2014; 34(4):685-703. PMC: 4314453. DOI: 10.1002/sim.6370. View

2.
Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

3.
Esteva A, Kuprel B, Novoa R, Ko J, Swetter S, Blau H . Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017; 542(7639):115-118. PMC: 8382232. DOI: 10.1038/nature21056. View

4.
Bruno R, Mercier F, Claret L . Evaluation of tumor size response metrics to predict survival in oncology clinical trials. Clin Pharmacol Ther. 2014; 95(4):386-93. DOI: 10.1038/clpt.2014.4. View

5.
Fan F, Xiong J, Li M, Wang G . On Interpretability of Artificial Neural Networks: A Survey. IEEE Trans Radiat Plasma Med Sci. 2022; 5(6):741-760. PMC: 9105427. DOI: 10.1109/trpms.2021.3066428. View